Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits.
With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for approximately 25% of the Dutch population (1275 hospitalized cases) over the period June 2004-June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3-5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60yrs, from 26 cases in 60-64-yr-olds to 97 cases per 100,000 in persons > or =90yrs. Beyond the age of 4yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy.
Jansen
Angelique G S C
AG
Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, UMC Utrecht, The Netherlands. a.g.s.c.jansen@umcutrecht.nl
Rodenburg
Gerwin D
GD
de Greeff
Sabine C
SC
Hak
Eelko
E
Veenhoven
Reinier H
RH
Spanjaard
Lodewijk
L
Schouls
Leo M
LM
Sanders
Elisabeth A M
EA
van der Ende
Arie
A
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003625:Data Collection; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000276:immunology; D022242:Pneumococcal Vaccines / Q000276:immunology; D012189:Retrospective Studies
D022242:Pneumococcal Vaccines